Novel active substance launches
79Global, 2025
Source: IQVIA
ISIC C21 · Industry hub · 19 publishers
Pharmaceuticals statistics
671 verified figures across 358 measures of the pharmaceuticals industry, from 19 publishers in 14 regions. Every number opens the report and sentence it was taken from.
Phase I small molecule clinical trial share
62%Global, 2025
+2 ppsince 2023
Source: IQVIA
Global, 2022
Source: IFPMA
Novel drug approvals meeting user fee goal dates
47United States, 2024
Source: FDA
Key findings
The most quotable figures in this dataset, each with its publisher. Copy a citation or open the record to read the source sentence.
Market size and output 13
- Medicine spending worldwide was 1.6 trillion USD in 2023 (IQVIA). IQVIA ↗
- Cardiometabolic RNA and next-generation lipid drug trial starts worldwide were 30 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- Active cardiometabolic RNA and next-generation lipid drug trials worldwide were 90 (ClinicalTrials.gov, published 27 September 2026). ClinicalTrials.gov ↗ T1 Official
- Phase 3 cardiometabolic RNA and next-generation lipid drug trials worldwide were 103 (ClinicalTrials.gov, published 27 September 2026). ClinicalTrials.gov ↗ T1 Official
- Registered interventional cardiometabolic RNA and next-generation lipid drug trials worldwide were 237 (ClinicalTrials.gov, published 27 September 2026). ClinicalTrials.gov ↗ T1 Official
- Cell and gene therapy spending worldwide was 5.9 billion USD in 2023 (IQVIA). IQVIA ↗
- Alzheimer's disease drug trial starts worldwide were 78 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- Antibody-drug conjugate trial starts worldwide were 349 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- Autoimmune cell therapy and T-cell engager trial starts worldwide were 112 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- GLP-1, incretin multi-agonist and amylin trial starts worldwide was 223 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- Gene editing trial starts worldwide were 35 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- Inflammatory bowel disease drug trial starts worldwide were 94 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
- KRAS and RAS inhibitor trial starts worldwide were 56 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official
Growth and change 1
- IQVIA projects high GDP developed countries medicine spending growth worldwide at 155.1 billion constant USD in 2026–2030. IQVIA ↗
Charts
The best-covered series in this dataset. Every chart can be embedded with its attribution line, and its underlying data is one click below it.
Alzheimer's disease drug trial starts
Global, 2020 to 2025
Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org
Median drug approval time by country
2025 · 5 countries
View the underlying data
| Category | Source | Type | Value |
|---|---|---|---|
| Switzerland | CIRS | Actual | 413 days |
| Canada | CIRS | Actual | 369 days |
| Australia | CIRS | Actual | 350 days |
| United States | CIRS | Actual | 322 days |
| Japan | CIRS | Actual | 292 days |
Source: CIRS · days · CC BY 4.0 · statorigin.org
New active substance approvals by country
2025 · 5 countries
View the underlying data
| Category | Source | Type | Value |
|---|---|---|---|
| United States | CIRS | Actual | 50 |
| Canada | CIRS | Actual | 44 |
| Australia | CIRS | Actual | 42 |
| Japan | CIRS | Actual | 40 |
| Switzerland | CIRS | Actual | 34 |
Source: CIRS · CC BY 4.0 · statorigin.org
Antibody-drug conjugate trial starts
Global, 2020 to 2025
Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org
Pharmaceuticals statistics by topic
Each topic gathers one measure across every country and year, with its own country pages and rankings.
- 127 measures · 2 country pages269Clinical trial starts
- 58 measures · 2 country pages39New drug approvals
- 42 measures · 1 country page31,097Clinical trial registrations
- 18 measures · 1 country page0.6%Medicine spending
- 13 measures · 2 country pages79New medicine launches
- 12 measures · 1 country page199Reimbursement list additions
- 3 measures · 1 country page27%Clinical trial locations by country
- 6 measures · 1 country page3,253Drugs on reimbursement lists
- 6 measures · 1 country page210 billiondays of therapyMedicine use
- 8 measures · 1 country page125,986 millionUSDPharmaceutical R&D investment
Every measure in this dataset
Latest value for each measure, the change from the previous period, and its trend. The full records, with provenance columns, are in the CSV download.
Clinical trial starts 127
Total number of clinical trials initiated during a given period. 127 slices on this page.
Show 119 more measures
- Oncology bispecific antibody trial starts 985
- Radioligand therapy trial starts 291
- Phase I small molecule clinical trial share 62%
- Large company small molecule share of Phase I clinical trial starts 66%
- Cell and gene therapy clinical trial starts 631
- Antibody-drug conjugate trial starts since 2023: Breast cancer 315
- Antibody-drug conjugate trial starts since 2023: Gastric or oesophageal cancer 121
- Antibody-drug conjugate trial starts since 2023: Lung cancer 193
- Antibody-drug conjugate trial starts since 2023: Lymphoma 119
- Antibody-drug conjugate trial starts since 2023: Ovarian, cervical or endometrial cancer 195
- Antibody-drug conjugate trial starts since 2023: Urothelial or bladder cancer 116
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Immune thrombocytopenia or autoimmune haemolytic anaemia 26
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Multiple sclerosis 25
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Myasthenia gravis 29
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Systemic lupus erythematosus / lupus nephritis 147
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Systemic sclerosis 68
- Autoimmune cell therapy and T-cell engager trial starts since 2023: Vasculitis 39
- Gene editing trial starts since 2023: Cancer 36
- Gene editing trial starts since 2023: Inherited eye disease 5
- Gene editing trial starts since 2023: Inherited liver and metabolic disease 17
- Gene editing trial starts since 2023: Sickle cell disease or beta-thalassaemia 18
- GLP-1, incretin multi-agonist and amylin trial starts since 2023: Alcohol or substance use 31
- GLP-1, incretin multi-agonist and amylin trial starts since 2023: Chronic kidney disease 21
- GLP-1, incretin multi-agonist and amylin trial starts since 2023: Heart failure or cardiovascular disease 73
- GLP-1, incretin multi-agonist and amylin trial starts since 2023: MASH / NASH 33
- GLP-1, incretin multi-agonist and amylin trial starts since 2023: Obesity or overweight 468
- GLP-1, incretin multi-agonist and amylin trial starts since 2023: Type 2 diabetes 228
- Inflammatory bowel disease drug trial starts since 2023: Crohn's disease 154
- Inflammatory bowel disease drug trial starts since 2023: Ulcerative colitis 224
- KRAS and RAS inhibitor trial starts since 2023: Advanced solid tumours (basket) 89
- KRAS and RAS inhibitor trial starts since 2023: Colorectal cancer 55
- KRAS and RAS inhibitor trial starts since 2023: Non-small cell lung cancer 93
- KRAS and RAS inhibitor trial starts since 2023: Pancreatic cancer 79
- Oncology bispecific antibody trial starts since 2023: Breast cancer 51
- Oncology bispecific antibody trial starts since 2023: Gastric, oesophageal or colorectal cancer 156
- Oncology bispecific antibody trial starts since 2023: Liver or biliary cancer 60
- Oncology bispecific antibody trial starts since 2023: Lung cancer 194
- Oncology bispecific antibody trial starts since 2023: Lymphoma 184
- Oncology bispecific antibody trial starts since 2023: Multiple myeloma 132
- Oncology clinical trial starts 2,162
- Oncology share of all clinical trials 41%
- Radioligand therapy trial starts since 2023: Breast cancer 25
- Radioligand therapy trial starts since 2023: Kidney cancer 13
- Radioligand therapy trial starts since 2023: Lung cancer 25
- Radioligand therapy trial starts since 2023: Neuroendocrine tumours 49
- Radioligand therapy trial starts since 2023: Prostate cancer 145
- Trial starts since 2023: Actinium-225 agents (alpha) 48
- Trial starts since 2023: Adagrasib (G12C) 25
- Trial starts since 2023: Agitation and psychosis in Alzheimer's 7
- Trial starts since 2023: Allogeneic or universal 72
- Trial starts since 2023: Amivantamab (EGFR x MET) 32
- Trial starts since 2023: Amycretin 22
- Trial starts since 2023: ANGPTL3 (zodasiran, solbinsiran) 4
- Trial starts since 2023: Anti-amyloid antibodies (all) 21
- Trial starts since 2023: Anti-integrin (vedolizumab and others) 24
- Trial starts since 2023: Anti-TL1A antibodies 21
- Trial starts since 2023: APOC3 (olezarsen, plozasiran) 7
- Trial starts since 2023: Base editing 35
- Trial starts since 2023: BCMA x CD3 T-cell engagers 99
- Trial starts since 2023: BCMA-directed 96
59 further measures are in the CSV download.
Drug approvals 58
Total number of therapeutic drugs granted regulatory marketing approval. 58 slices on this page.
Common new active substance approvals across major regulatory authorities (multi-year total) 52 +41% since 2016–2020 CIRS 2 records
Show 50 more measures
- Domestic first-in-class drug approvals 4
- Domestic innovative biological product approvals 21
- Domestic innovative chemical drug approvals 38
- Domestic innovative drug approvals (half year) 31
- Domestic share of approved innovative biological products 91.3%
- Domestic share of approved innovative chemical drugs 80.8%
- Imported innovative biological product approvals 2
- Imported innovative chemical drug approvals 9
- Innovative biological product approvals 23
- Innovative drug approvals (half year) 38
- Innovative drugs approved via priority review pathway 17
- Innovative drugs granted conditional market approval 11
- Innovative traditional medicine approvals 6
- Antibody-drug conjugate approvals 3
- Approved Class 1 innovative drugs 76
- Approved Class 1 innovative drugs (half year) 38
- Approved innovative drugs with new targets or mechanisms 11
- Approved innovative drugs with new targets or mechanisms (half year) 11
- Approved novel drugs in breakthrough therapy programs 13
- Biosimilar biological product approvals 18
- Bispecific antibody approvals 4
- Breast cancer drug approvals 9
- Cell therapy approvals 3
- Domestic developer drug approvals 63
- Domestic developer share of drug approvals 52%
- First global drug approvals 61
- First-cycle novel drug approvals 37
- Fusion protein approvals 3
- Generic medicines receiving positive opinion (monthly) 3
- Human medicines recommended for marketing authorization 104
- Human medicines recommended for marketing authorization with new active substance 38
- Human rare disease medicines recommended for marketing authorisation 16
- Imported drug share of approvals 48%
- Innovative biological product approvals (half year) 17
- Innovative drug approvals (year to date) 14
- Innovative traditional medicine approvals (half year) 1
- Interchangeable biosimilar approvals 9
- New drugs approved for marketing after clinical trials (China registration category) 248
- Novel antibiotic approvals 3
- Novel drug approvals meeting user fee goal dates 47
- Novel drug approvals using expedited programs 33
- Novel drug approvals via priority review pathway 17
- Novel drugs approved first in domestic market 34
- Novel drugs granted conditional market approval 11
- Rare disease drug varieties approved 39
- Share of first-cycle novel drug approvals 74%
- Share of novel drug approvals meeting user fee goal dates 94%
- Share of novel drug approvals using expedited programs 66%
- Share of novel drugs approved first in domestic market 68%
- Approved innovative drugs growth rate 58.3%
Clinical trial registrations 42
Total number of clinical trials registered with a clinical trials registry platform. 42 slices on this page.
Show 34 more measures
- Active inflammatory bowel disease drug trials 372
- Active KRAS and RAS inhibitor trials 217
- Active oncology bispecific antibody trials 1,109
- Active radioligand therapy trials 323
- Bioequivalence trials 2,218
- Bioequivalence trials share 42.5%
- Class 1 innovative drug clinical trials 2,171
- Class 1 innovative drug clinical trials share 72.4%
- International multi-center clinical trials 410
- New drug clinical trials share 57.5%
- Phase 3 Alzheimer's disease drug trials 332
- Phase 3 antibody-drug conjugate trials 355
- Phase 3 autoimmune cell therapy and T-cell engager trials 8
- Phase 3 cardiometabolic RNA and next-generation lipid drug trials 103
- Phase 3 gene editing trials 11
- Phase 3 GLP-1, incretin multi-agonist and amylin trials 535
- Phase 3 inflammatory bowel disease drug trials 449
- Phase 3 KRAS and RAS inhibitor trials 36
- Phase 3 oncology bispecific antibody trials 160
- Phase 3 radioligand therapy trials 51
- Registered interventional Alzheimer's disease drug trials 1,646
- Registered interventional antibody-drug conjugate trials 2,351
- Registered interventional autoimmune cell therapy and T-cell engager trials 336
- Registered interventional cardiometabolic RNA and next-generation lipid drug trials 237
- Registered interventional gene editing trials 262
- Registered interventional GLP-1, incretin multi-agonist and amylin trials 1,963
- Registered interventional inflammatory bowel disease drug trials 1,698
- Registered interventional KRAS and RAS inhibitor trials 322
- Registered interventional oncology bispecific antibody trials 1,525
- Registered interventional radioligand therapy trials 577
- Retrospectively registered clinical trials 5,326
- Class 1 innovative drug clinical trials growth rate 4.1%
- Clinical trial registrations growth rate 6.4%
- New drug clinical trials growth rate 18%
Medicine spending 19
Total expenditure on pharmaceutical products and therapies. 19 slices on this page.
Show 11 more measures
- Cell and gene therapy spending growth rate 38%
- Cell and gene therapy spending year-over-year growth 38%
- COVID-19 vaccines and therapeutics spending decline 4 billion USD
- GIP/GLP-1 agonist spending growth contribution 14 billion USD
- High GDP developed countries medicine spending growth 155.1 billion constant USD
- Medicine spending growth rate lower bound 5%
- Medicine spending growth rate upper bound 8%
- Net medicine spending increase 58 billion USD
- Obesity-approved GIP and GLP-1 agonist medicine spending growth 9.6 billion USD
- Patient out-of-pocket medicine cost increase 6 billion USD
- Projected net medicine spending increase 200 billion USD
Novel active substance launches 13
Total number of novel active substances launched on the market. 13 slices on this page.
Formulary additions 12
Total number of new pharmaceutical products added to a reimbursement formulary or drug list. 12 slices on this page.
Research and development investment 8
Total capital and operational expenditure allocated to research and development activities. 8 slices on this page.
Pharmaceutical and medicine manufacturing total R&D performance 125,986 million USD +8.5% since 2022 NCSES 2 records
Pharmaceutical and medicine manufacturing R&D funded by domestic companies 2,104 million USD NCSES 1 record
Pharmaceutical and medicine manufacturing R&D funded by foreign companies 9 billion USD NCSES 1 record
Pharmaceutical and medicine manufacturing R&D funded by other external sources 79 million USD NCSES 1 record
Formulary drugs 6
Total number of pharmaceutical products covered by a reimbursement formulary or drug list. 6 slices on this page.
Medicine use 6
Total volume or quantity of medicines utilized by a population. 6 slices on this page.
Drug approval applications 4
Total number of regulatory applications reviewed for drug marketing authorization. 4 slices on this page.
Employment 4
Total number of individuals employed within a specified industry sector or facility. 4 slices on this page.
Gross value added 4
Total monetary value of goods and services produced less intermediate consumption. 4 slices on this page.
Medicines in clinical development 4
Total number of drug candidates actively evaluated in clinical trials. 4 slices on this page.
Clinical trial country uses 3
Total number of country participations across clinical trials. 3 slices on this page.
Formulary removals 3
Total number of pharmaceutical products removed or delisted from a reimbursement formulary or drug list. 3 slices on this page.
Out-licensing deal value 3
Total monetary value of out-licensing agreements signed for pharmaceutical assets. 3 slices on this page.
Out-licensing deals 3
Total number of out-licensing agreements concluded for pharmaceutical assets. 3 slices on this page.
Sales 3
Total monetary amount of sales revenue generated. 3 slices on this page.
Clinical trial approval timeliness 2
Share of clinical trial applications receiving regulatory approval decisions within standard timeframes. 2 slices on this page.
Drug approval time 2
Duration required by a regulatory authority to approve a drug marketing application. 2 slices on this page.
New drug market entrants 2
Total number of new pharmaceutical products entering a market for the first time. 2 slices on this page.
Patient burden reduction 2
Total out-of-pocket healthcare expense savings experienced by patients through price reductions or coverage. 2 slices on this page.
Pharmaceutical delivery value 2
Total monetary value of pharmaceutical products delivered by manufacturers. 2 slices on this page.
Price negotiation drugs 2
Number of drugs participating in price negotiations or competitive bidding for reimbursement coverage. 2 slices on this page.
Sales clawback cap 2
Statutory or agreed ceiling on revenue clawback rates applied to pharmaceutical sales. 2 slices on this page.
Venture and public funding deals 2
Total number of venture capital and public funding transactions completed. 2 slices on this page.
Cell and gene therapy venture capital and public funding deal count 96 −1% since 2022 IQVIA 3 records
Measures with one series 20
One slice each, so they have nothing to add up with on this page.
Cumulative health insurance fund payout for negotiated medicines 350 billion CNY State Council 1 record
Show 12 more measures
- Life sciences and patient organization deal value 2.4 billion USD
- Life sciences and patient organization deals 700
- New medicines recommended for approval (monthly) 12
- Pharmaceutical and medicine manufacturing R&D intensity 17.8%
- Pharmaceutical industry investment commitments 2 billion GBP
- Reference products with biosimilar approvals 8
- Severe influenza cases 5 million
- Top 50 global pharmaceutical companies count 6
- Pharmaceutical value-added industrial output growth (half year) 6.4%
- Clinical trial patient recruitment change -25%
- Inter-trial interval increase 3 months
- Oncology clinical development productivity growth 51%
358 measures. Each name opens the full series; each value opens the record with its source evidence.
Answered from the data
Common questions
How big is the global pharmaceuticals market?
Medicine spending worldwide was 1.6 trillion USD in 2023 (IQVIA).
How fast is the pharmaceuticals market growing?
Cell and gene therapy spending growth rate worldwide was 38% in 2023 (IQVIA).
What is the forecast for pharmaceuticals?
IQVIA projects medicine spending growth rate lower bound worldwide at 5% in 2026–2030.
Where does this pharmaceuticals data come from?
Every figure on this page traces to a primary source: 19 organisations publish the underlying data, and the observed figures span 1999 to 2026, with projections to 2035. The full source table lists each report, its publication date and the original link.
How often is this page updated?
The dataset was last verified on 27 September 2026. Annual series are refreshed when the publisher releases a new edition; corrections are accepted at any time and answered within 48 hours.
Which countries have the most pharmaceuticals data?
9 countries have at least one pharmaceuticals figure on this page. The best covered are China (229 records), the United States (116) and the United Kingdom (14).
Sources
Every document behind this page, with the date we read it and whether the link still resolves. All 671 collected records are published as verified.
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in gastric or oesophageal cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in ovarian, cervical or endometrial cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) in urothelial or bladder cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in immune thrombocytopenia or autoimmune haemolytic anaemia, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in multiple sclerosis, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in myasthenia gravis, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in myasthenia gravis, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic lupus erythematosus / lupus nephritis, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic lupus erythematosus / lupus nephritis, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic sclerosis, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in systemic sclerosis, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in vasculitis, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer in vasculitis, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in alcohol or substance use, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in alcohol or substance use, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in chronic kidney disease, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in chronic kidney disease, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in heart failure or cardiovascular disease, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in heart failure or cardiovascular disease, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in mash / nash, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in mash / nash, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in obesity or overweight, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in obesity or overweight, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in type 2 diabetes, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in type 2 diabetes, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited eye disease, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited eye disease, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited liver and metabolic disease, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in inherited liver and metabolic disease, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product in sickle cell disease or beta-thalassaemia, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified in crohn's disease, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified in crohn's disease, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified in ulcerative colitis, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified in ulcerative colitis, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in advanced solid tumours (basket), with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in advanced solid tumours (basket), with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in colorectal cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in colorectal cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in non-small cell lung cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in non-small cell lung cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in pancreatic cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) in pancreatic cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in breast cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in gastric, oesophageal or colorectal cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in gastric, oesophageal or colorectal cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in liver or biliary cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in liver or biliary cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lung cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in lymphoma, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in multiple myeloma, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) in multiple myeloma, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in any country Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in any country. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in breast cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in breast cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in kidney cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in kidney cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in lung cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in lung cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in neuroendocrine tumours, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in neuroendocrine tumours, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in prostate cancer, with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy in prostate cancer, with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional drug or biologic studies in Alzheimer's disease, any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional drug or biologic studies in Alzheimer's disease, any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes), any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes), any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents), any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents), any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others), any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer, any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer, any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease, any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease, any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product, any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product, any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified, any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified, any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others), any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others), any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: All interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy, any start date, as registered on 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: All interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy, any start date, as registered on 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of ANGPTL3 (zodasiran, solbinsiran) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of ANGPTL3 (zodasiran, solbinsiran) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of APOC3 (olezarsen, plozasiran) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of APOC3 (olezarsen, plozasiran) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Actinium-225 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Actinium-225 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Adagrasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Adagrasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Agitation and psychosis in Alzheimer's (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Agitation and psychosis in Alzheimer's (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Allogeneic or universal (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Allogeneic or universal (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Amivantamab (EGFR x MET) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Amivantamab (EGFR x MET) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Amycretin (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Amycretin (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Anti-TL1A antibodies (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Anti-TL1A antibodies (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Anti-amyloid antibodies (all) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Anti-amyloid antibodies (all) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Anti-integrin (vedolizumab and others) (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Anti-integrin (vedolizumab and others) (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of BCMA x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of BCMA x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of BCMA-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of BCMA-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of BL-B01D1 (EGFR x HER3 bispecific ADC) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of BL-B01D1 (EGFR x HER3 bispecific ADC) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Base editing (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Base editing (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CAR-NK (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CAR-NK (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CD19-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CD19-directed (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CD20 x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CD20 x CD3 T-cell engagers (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Cadonilimab (PD-1 x CTLA-4) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Cadonilimab (PD-1 x CTLA-4) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of CagriSema / cagrilintide (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of CagriSema / cagrilintide (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Daraxonrasib (pan-RAS) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Daraxonrasib (pan-RAS) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Datopotamab deruxtecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Datopotamab deruxtecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Disitamab vedotin (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Disitamab vedotin (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Divarasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Divarasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Donanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Donanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Enfortumab vedotin (Nectin-4) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Enfortumab vedotin (Nectin-4) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Ex vivo edited stem cells (sickle cell, thalassaemia) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Ex vivo edited stem cells (sickle cell, thalassaemia) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of GLP-1 receptor agonists (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of GLP-1 receptor agonists (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Garsorasib, fulzerasib and glecirasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Garsorasib, fulzerasib and glecirasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Gene-edited CAR-T or TCR-T (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Gene-edited CAR-T or TCR-T (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of IL-23 p19 antibodies (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of IL-23 p19 antibodies (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of In vivo liver editing (LNP) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of In vivo liver editing (LNP) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Inclisiran (PCSK9 siRNA) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Inclisiran (PCSK9 siRNA) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Ivonescimab (PD-1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Ivonescimab (PD-1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of JAK inhibitors (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of JAK inhibitors (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of KRAS G12D-directed agents (inhibitors, degraders, vaccines, cell therapies) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of KRAS G12D-directed agents (inhibitors, degraders, vaccines, cell therapies) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Lead-212 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Lead-212 agents (alpha) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Lecanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Lecanemab (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Lp(a) lowering (olpasiran, lepodisiran, zerlasiran, pelacarsen, muvalaplin) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Lp(a) lowering (olpasiran, lepodisiran, zerlasiran, pelacarsen, muvalaplin) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Lutetium-177 agents (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Lutetium-177 agents (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of MariTide (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of MariTide (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Mazdutide (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Mazdutide (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Obefazimod (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Obefazimod (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Obicetrapib (CETP) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Obicetrapib (CETP) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Olomorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Olomorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Oral IL-23 receptor peptide (icotrokinra) (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Oral IL-23 receptor peptide (icotrokinra) (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Oral PCSK9 inhibitors (enlicitide, AZD0780) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Oral PCSK9 inhibitors (enlicitide, AZD0780) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Orforglipron (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Orforglipron (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of PD-(L)1 x VEGF bispecifics (all) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of PD-(L)1 x VEGF bispecifics (all) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of PSMA-targeted (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of PSMA-targeted (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Pumitamig / BNT327 (PD-L1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Pumitamig / BNT327 (PD-L1 x VEGF) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Radium-223 (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Radium-223 (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Retatrutide (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Retatrutide (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of S1P modulators (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of S1P modulators (within: interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of SHR-A1811 / trastuzumab rezetecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of SHR-A1811 / trastuzumab rezetecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Sacituzumab govitecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Sacituzumab govitecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Sacituzumab tirumotecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Sacituzumab tirumotecan (TROP2) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Semaglutide (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Semaglutide (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Somatostatin-receptor-targeted (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Somatostatin-receptor-targeted (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Sotorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Sotorasib (G12C) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of T-cell engagers (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of T-cell engagers (within: interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of TTR silencers (vutrisiran, patisiran, eplontersen, nucresiran) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of TTR silencers (vutrisiran, patisiran, eplontersen, nucresiran) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Tarlatamab (DLL3 x CD3) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Tarlatamab (DLL3 x CD3) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Tau-targeted therapies (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Tau-targeted therapies (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Tirzepatide (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Tirzepatide (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Trastuzumab deruxtecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Trastuzumab deruxtecan (HER2) (any indication) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| ClinicalTrials.gov study count: Interventional studies of Trontinemab (brain shuttle) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27 Dataset | ClinicalTrials.gov | T1 Official | — | 27 Sep 2026 | totalCount field of the API response. Query: Interventional studies of Trontinemab (brain shuttle) (within: interventional drug or biologic studies in Alzheimer's disease) with a start date from 2023-01-01 to 2026-09-27. | 1 |
| The 2025 EU Industrial R&D Investment Scoreboard Press release | European Commission | T1 Official | 22 Dec 2025 | 17 Sep 2026 | EU: Health and energy sectors shine in a year of slowdown | 2 |
| Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026 Press release | EMA | T1 Official | — | 15 Sep 2026 | Twelve new medicines recommended for approval | 2 |
| EMA’s 2025 annual report shows strong approval numbers for human and veterinary medicines Press release | EMA | T1 Official | — | 17 Sep 2026 | EMA’s 2025 annual report shows strong approval numbers for human and veterinary medicines | 3 |
| 2025年我国批准创新药76个 对外授权超千亿美元 Press release | MOFCOM | T1 Official | — | 17 Sep 2026 | 2025年我国批准创新药76个 对外授权超千亿美元 | 18 |
| 上半年我国创新药对外技术授权交易额创新高 Press release | MOFCOM | T1 Official | — | 17 Sep 2026 | 上半年我国创新药对外技术授权交易额创新高 | 7 |
| Business R&D Performance in the United States Increases to $722 Billion in 2023 Press release | NCSES | T1 Official | — | 17 Sep 2026 | Table 2. Funds spent for business R&D performed in the United States, by source of funds, selected industry, and company size: 2023; R&D Performance, by Type of R&D, Industry Sector, and Source of Funding; Sales, R&D Intensity, and Employment of Companies That Performed or Funded R&D | 7 |
| Discovery: R&D Activity and Research Publications Press release | NCSES | T1 Official | — | 17 Sep 2026 | Table DISC-3. Domestic net sales, R&D, and R&D-to-sales ratio for companies that performed or funded U.S. business R&D, by selected industry: 2022 | 1 |
| 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 Press release | NHSA | T1 Official | 28 Nov 2024 | 17 Sep 2026 | 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 | 12 |
| 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 大众新闻大众日报记者提问; 红星新闻记者提问 | 4 |
| 我国上半年创新药对外授权交易额超千亿美元 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产; 我国上半年创新药对外授权约1100亿美元 创历史新高; 11款新靶点新机制创新药涵盖哪些治疗领域 | 11 |
| 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 试验包括新药临床试验和生物等效性试验; 新药临床试验近六成 其中超七成是创新药; 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 | 12 |
| 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 | 6 |
| 创新高！去年我国批准创新药76个 对外授权破千亿美元 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 创新高！去年我国批准创新药76个 对外授权破千亿美元 | 16 |
| Measures facilitate approval of 48 first-in-class innovative drugs Press release | NMPA | T1 Official | — | 17 Sep 2026 | Measures facilitate approval of 48 first-in-class innovative drugs | 11 |
| China approves 48 innovative drugs in 2024 Press release | NMPA | T1 Official | — | 17 Sep 2026 | China approves 48 innovative drugs in 2024 | 6 |
| Business enterprise research and development, UK Press release | ONS | T1 Official | — | 17 Sep 2026 | Main points | 1 |
| China updates national medical insurance catalog, adds 114 new drugs Press release | SCIO | T1 Official | — | 17 Sep 2026 | China updates national medical insurance catalog, adds 114 new drugs | 4 |
| Measures facilitate approval of 48 first-in-class innovative drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | Measures facilitate approval of 48 first-in-class innovative drugs | 11 |
| 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网 Press release | State Council | T1 Official | — | 17 Sep 2026 | 7年累计将835种药品新增进入目录; 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药; “全球新”的创新药有38种，创历年新高 | 10 |
| Value of China's innovative drug out-licensing deals hit new high in H1 Press release | State Council | T1 Official | — | 17 Sep 2026 | Value of China's innovative drug out-licensing deals hit new high in H1 | 4 |
| China updates national medical insurance catalog, adds 114 new drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | China updates national medical insurance catalog, adds 114 new drugs | 4 |
| 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网 Press release | State Council | T1 Official | — | 17 Sep 2026 | 大力支持产业创新; 更好满足临床急需 | 2 |
| China to expand health insurance coverage for innovative drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | China to expand health insurance coverage for innovative drugs | 6 |
| CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 Press release | FDA | T1 Official | — | 17 Sep 2026 | A Record Year for Biosimilar Approvals; CDER’s Effectiveness Bringing New Therapies to Market; Creating a Yearly Snapshot for Approvals | 13 |
| Novel Drug Approvals for 2025 Press release | FDA | T1 Official | — | 17 Sep 2026 | FDA Novel Drug Therapy Approvals for 2025 | 1 |
| Novel Drug Approvals for 2024 Press release | FDA | T1 Official | — | 17 Sep 2026 | FDA Novel Drug Therapy Approvals for 2024 | 1 |
| Number of clinical trials by year, country, WHO region and income group (1999-2022) Press release | WHO | T1 Official | — | 17 Sep 2026 | Points to note: | 5 |
| Green shoots for UK pharma investment, but delivery will decide whether they take root Press release | ABPI | T2 Official | — | 17 Sep 2026 | UK competitive weaknesses; UK areas of unrealised potential; Green shoots for UK pharma investment, but delivery will decide whether they take root | 13 |
| 2025 NMPA Approvals: China Clears Record Number of New Drugs Press release | DIA | T2 Official | — | 17 Sep 2026 | Established Modalities Maintain a Larger Presence; The Cancer Sector Continues to Attract the Most Players; Domestic Players Account for Most of China’s Approvals | 11 |
| Enabling innovation: The R&D ecosystem for medicines and vaccines Press release | IFPMA | T2 Official | — | 15 Sep 2026 | Enabling innovation: The R&D ecosystem for medicines and vaccines | 7 |
| Neue Medikamente in Deutschland: Innovationsbilanz 2025 Press release | VFA | T2 Official | — | 17 Sep 2026 | Herstellungsarten; Innovationsbilanz 2025; Medikamente gegen seltene Erkrankungen | 5 |
| New Drug Approvals by Six Major Authorities 2016-2025 Press release | CIRS | T3 Research | — | 17 Sep 2026 | Key Findings | 14 |
| GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data Press release | GSK | T3 Research | — | 15 Sep 2026 | About seasonal flu | 2 |
| U.S. Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Other Findings; Key Findings | 13 |
| Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Cell and gene therapy clinical trial starts by type, 2013-2023; Key findings; Global cell and gene therapy spending and share by geography | 17 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025; Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025; Key Findings | 19 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025; The number of novel active substance (NAS) launches increased on a global basis; Key Findings: | 17 |
| Rethinking Clinical Trial Country Prioritization Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Key findings:; Country utilization is heavily consolidated in U.S., China and Western European countries | 9 |
| Global Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 20: High growth developed and Pharmerging markets spending and growth,constant US$, 2015–2030; Exhibit 15: Global medicine market size and growth including estimated COVID-19 vaccine and therapeutic spending, 2016–2030; Report Summary: | 10 |
| Supporting patients through research collaboration Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Key findings:; Patient organizations now provide input into 21% of all drug health technology assessments (HTAs) globally and up to 52% in some therapy areas in EU and Commonwealth countries. | 4 |
| IQVIA Institute’s Global R&D Trends 2026 Report Finds Credible Signal on AI-Enabled Programs Press release | IQVIA | T3 Research | — | 17 Sep 2026 | IQVIA Institute’s Global R&D Trends 2026 Report Finds Credible Signal on AI-Enabled Programs | 1 |
| Global Oncology Trends 2025 Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Key Findings: Oncology clinical development productivity has improved but remains challenging; Key Findings: Oncology R&D activity continues to grow driven by novel modalities; Other Findings | 3 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
12 further figures come from companies reporting on their own results and operations. They describe one company rather than the industry, so they are not part of this page. They stay published, with their sources: GSK, J&J, Roche, Sanofi.
Cite and reuse
Published under CC BY 4.0. Reuse is free, including commercially, with attribution.
StatOrigin. (2026). Pharmaceuticals Industry Statistics. Retrieved from https://statorigin.org/industries/pharmaceuticals
Found an error? Report it. We answer within 48 hours and log every correction on the corrections page.